Administration of vincristine in a patient with Machado-Joseph disease

1Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Chemotherapy-induced peripheral neurotoxicity is a major problem because it represents the dose-limiting side effect of a significant number of antineoplastic drugs, such as vinca alkaloids. Hereditary neuropathies usually predispose to severe vincristine neurotoxicity. Here, we report the case of a 56-year-old man with Machado-Joseph disease, also known as spinocerebellar ataxia type 3, treated with a vinca alkaloid without exacerbation of neurological symptoms. Copyright © 2012 S. Karger AG, Basel.

Cite

CITATION STYLE

APA

Colpo, A., Wilson, F. H., Nardi, V., & Hochberg, E. (2012). Administration of vincristine in a patient with Machado-Joseph disease. Oncology, 82(3), 165–167. https://doi.org/10.1159/000336602

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free